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Abstracts / Biol Blood Marrow Transplant 21 (2015) S171eS184 S183Results: At two weeks post-HSCT cytokine levels did not
differ between the groups. Neither did the groups differ in
long-term outcome in terms of general wellbeing, immu-
noglobulin response to vaccinations and in the most central
phenotypic features of the immune system (e.g., differenti-
ation status, CD4/CD8 ratio, B and NK cell frequency). More
than 5 years post-HSCT, MC patients had signiﬁcantly higher
NKT cell levels (CD94+CD8+ and CD56+CD8+ T cells) than DC
patients. In-depth analysis of the MC patients revealed that
recipient chimerism could be observed in a large variety of
immune cell lineages (i.e., total, CD4+, CD8+ and gd T cells; B
cells; NK cells; myeloid cells; and cytokine producing cells).
Furthermore, the recipient chimerism in different cell line-
ages were positively correlated with each other, e.g., an in-
crease in CD3 chimerism was associated to an increase in
CD56 chimerism. Both recipient and donor derived cells in
MC patients produced cytokines to the same degree in
response to mitogen stimulation. No difference in mitogen
response was observed between the groups.
Discussion: Long-term MC does not appear to negatively
affect the wellbeing of the patients. It could even be argued
that the recipient system has a more differentiated pheno-
type than the donor system, indicating that MC might be of
beneﬁt protecting against infections. The recipient immune
system may still be functional in MC patients, as both
recipient and donor derived cells responded to mitogens.
Two scenarios could explain such a symbiotic relationship
between donor and recipient system: a superﬂuous duplicity
of the entire immune system or an adjuvant role by the
recipient system to the donor system.236
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Development, Bethesda, MDFigure.In caring for female patients undergoing hematopoietic stem
cell transplant (HSCT), it is important to consider all aspects of
reproductive health from fertility to contraception to sexu-
ality and quality of life. Individual counseling on future
fertility is part of routine pre-transplant care. Given the var-
iable urgency with which a HSCT is undertaken and a pa-
tient’s fertility desires, fertility preservation needs and
options will vary from patient to patient. Additionally in
reproductive-age women, it is important to achieve thera-
peutic amenorrhea as well as provide effective contraception
during the HSCT process given the iatrogenic thrombocyto-
penia and exposure to potential teratogenic agents. Hormonal
therapies such as gonadotropin-releasing hormone agonists
(GnRHa), combined contraceptives, and progestin-only
methods initiated prior to transplant can each provide con-
traceptive and non-contraceptive beneﬁts for pre-meno-
pausal women. In particular, GnRHa are shown to be highly
effective in achieving therapeutic amenorrhea, especially
when started two to four weeks prior to the conditioning
regimen. Often, a single three-month dose achieves amen-
orrhea from the pre-HSCT period through engraftment. A
potential additional beneﬁt of GnRHa may be preserving
ovarian function, especially for those undergoing reduced-
intensity conditioning, though this effect is still under
investigation. Notably, the conditioning regimen is the only
gonadotoxic part of the HSCT process. Given its effectiveness
in achieving therapeutic amenorrhea, the availability of a
three-month dose, and the potential for ovarian preservation,
initiation of GnRHa warrants consideration in all pre-meno-
pausal women prior to transplant. During the pre-transplant
evaluation, gynecologists serve as valuable consultants in
addressing the appropriate timing of initiating GnRHa for
maximal beneﬁt, future fertility, contraception, therapeutic
amenorrhea, and peri-transplant reproductive health con-
cerns. During the post-transplant period through long-term
survivorship care, gynecologists can continue to address is-
sues such as revaccination for HPV, screening for genital
cancer and chronic graft versus host disease, hormone
replacement therapy, fertility, and sexuality. Gynecologists
have a role in addressing reproductive health concerns along
the entire spectrum of care for women undergoing hemato-
poietic stem cell transplant and are critical members of the
transplant team.
